Tissue Regenix Group is a pioneering, international medical technology company that is revolutionizing regenerative medicine. With a focus on developing regenerative products, their mission is to restore patient function and vitality. Tissue Regenix Group utilizes innovative platform technologies, including dCELL® and BioRinse™, to address clinical needs in the regenerative medicine market.

These complementary bone and soft tissue platforms trigger the body's own cells to enable natural tissue regeneration, offering a natural recovery process for patients. Tissue Regenix Group offers a range of regenerative products in key clinical areas such as BioSurgery, Orthopaedics, and Dental. Their business model allows them to deliver differentiated clinical outcomes and generate value for stakeholders.

Committed to sustainability, the company maintains a responsible and ethical approach in their operations. For investors seeking opportunities in the field of regenerative medicine, Tissue Regenix Group provides an investment case and performance information. The company also offers media resources for those who want to learn more about their groundbreaking work.

With a vision to become a leader in the science and innovation of regenerative medicine, Tissue Regenix Group is dedicated to transforming patient care and delivering favorable health economic outcomes